Overview

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and aspirin as part of a dual antiplatelet therapy (DAPT) drug regimen.
Phase:
Phase 4
Details
Lead Sponsor:
Medtronic Vascular
Treatments:
Aspirin
Clopidogrel
Platelet Aggregation Inhibitors
Prasugrel Hydrochloride